A5070479392- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Liver Disease and Transplantation
- Liver Diseases and Immunity
- Gastric Cancer Management and Outcomes
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Screening and Detection
- Liver physiology and pathology
- HIV/AIDS drug development and treatment
- interferon and immune responses
- Antimicrobial Resistance in Staphylococcus
- Antibiotics Pharmacokinetics and Efficacy
- Chronic Lymphocytic Leukemia Research
- Systemic Lupus Erythematosus Research
- Colorectal Cancer Surgical Treatments
- Inflammatory mediators and NSAID effects
- Economic and Financial Impacts of Cancer
- Eosinophilic Esophagitis
- Nutrition and Health in Aging
- Pancreatic and Hepatic Oncology Research
- Advanced Radiotherapy Techniques
- Bacterial Identification and Susceptibility Testing
- Digital Mental Health Interventions
- Telemedicine and Telehealth Implementation
Royal Adelaide Hospital
2016-2025
The University of Adelaide
2011-2025
Flinders University
2024
Royal Darwin Hospital
2020
SA Health
2016
Huntington Hospital
2010-2011
Centre for Cancer Biology
2011
South Australia Pathology
2011
University of California, Los Angeles
1991
Patients with hepatitis C virus (HCV) genotype 3 infection, especially those advanced liver disease, are a challenging population in urgent need of optimally effective therapies. The combination daclatasvir (DCV; pangenotypic nonstructural protein 5A inhibitor) and sofosbuvir (SOF; nucleotide 5B for 12 weeks previously showed high efficacy (96%) noncirrhotic infection. phase III ALLY-3+ study (N = 50) evaluated DCV-SOF ribavirin (RBV) treatment-naïve (n 13) or treatment-experienced 37)...
<h3>Importance</h3> The antiviral activity of all-oral, ribavirin-free, direct-acting regimens requires evaluation in patients with chronic hepatitis C virus (HCV) infection. <h3>Objective</h3> To determine the rates sustained virologic response (SVR) receiving 3-drug combination daclatasvir (a pan-genotypic NS5A inhibitor), asunaprevir (an NS3 protease and beclabuvir nonnucleoside NS5B inhibitor). <h3>Design, Setting, Participants</h3> This was an open-label, single-group, uncontrolled...
ABSTRACT Acute kidney injury (AKI) associated with high-dose vancomycin (VAN) therapy is a clinical concern, but no uniform diagnostic criteria exist. The AKI Network (AKIN) proposed new to diagnose based on abrupt changes in serum creatinine or urine output. We conducted prospective observational study determine the incidence and severity of outcomes using AKIN versus traditional definitions. Eligible patients ( n = 227) were elderly (median, 70 years) received VAN for 8 days (median)....
A barrier to hepatitis C virus (HCV) cure is conventional testing. The aim of this study was evaluate the effect HCV antibody and RNA point-of-care testing (POCT) on rates, linkage care, treatment, acceptability in 3 priority settings Australia.
Abstract Background In clinical trials, hepatitis C virus (HCV) salvage treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) achieved an SVR12 rate of &gt;95% in NS5A-experienced participants. Lower rates have been reported real-world studies, particularly for genotype (GT)3 infection and cirrhosis. We determined the efficacy safety SOF/VEL/VOX a large cohort. Methods assessed HCV NS5A-inhibitor experienced participants cirrhosis portal hypertension, prior liver...
In March 2016, the Australian government offered unrestricted access to direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) entire population. This included prescription by any medical practitioner in consultation with specialists until sufficient experience was attained. We sought determine outcomes and over first twelve months state of South Australia. performed a prospective, observational study following all treatments associated state's four main tertiary centres....
Background and aim The risk of local tumour progression (LTP) factors predicting LTP following percutaneous thermal ablation (PTA) early-stage hepatocellular carcinoma (HCC) have not been well studied in non-trial settings may be underestimated. We aimed to assess these outcomes a multicentre study. Patients methods This was retrospective review consecutive patients with HCC treated curative intent across three tertiary Australian centres between 2006 2012 either radiofrequency or microwave...
Summary Background Mycophenolate mofetil is a commonly used salvage therapy for patients with autoimmune hepatitis (AIH). Aim To evaluate the predictors of response to mycophenolate rescue facilitate clinical decision making. Methods We performed retrospective observational cohort study AIH managed in 17 major Australian liver centres who received after an inadequate or intolerance corticosteroids with/without thiopurine(s). Baseline demographic, and laboratory variables were compared...
Background and Aims: Improving the care of decompensated cirrhosis is a significant clinical challenge. The primary aim this trial was to assess efficacy chronic disease management (CDM) model reduce liver-related emergency admissions (LREA). secondary aims were effects on quality-of-care patient-reported outcomes. Approach Results: study design 2-year, multicenter, randomized controlled with 1:1 allocation CDM versus usual care. setting involved both tertiary community Participants randomly...
The pathogenesis of nonalcoholic steatohepatitis is primarily an immune-driven disease and a known factor associated with treatment failure chronic hepatitis C interferon (IFN) ribavirin. We studied the hepatocyte response in model steatosis at transcriptome level antiviral action IFN against virus (HCV) this setting. In study, we have shown that lipid loading (oleic acid palmitic acid, OA:PA) Huh-7 cells leads to increased expression classical interferon-stimulated genes (ISGs)...
To compare the incidence of liver-related emergency admissions and survival patients after hospitalisation for decompensated cirrhosis at two major hospitals, one applying a coordinated chronic disease management model (U1), other standard care (U2); to examine predictors mortality these patients.Retrospective observational cohort study.Two tertiary hospitals in an Australian capital city.Patients admitted with diagnosis during October 2013 - 2014, identified on basis International...
Background Limited data exist on the outcomes of ritonavir-boosted paritaprevir with ombitasvir and dasabuvir (PrOD) ± ribavirin in a real-world setting. The aim this study was to compare efficacy safety PrOD-based therapy hepatitis C genotype 1 patients without cirrhosis, explore pre-treatment factors predictive sustained viral response (SVR) serious adverse events (SAEs) treatment. Methods 451 treated 20 centres across Australia were included. Baseline demographic, clinical laboratory...
Shigella flexneri targets colonic cells in humans to initiate invasive infection processes that lead dysentery, and direct interactions between their lipopolysaccharide O antigens blood group A related glycans are involved the cell adherence interactions. Here, we show treatment with Tn sialyl-Tn glycans, monoclonal antibodies lectins reactive Tn/sialyl-Tn, luteolin (a antigen synthesis inhibitor) all significantly inhibited S. invasion of vitro. Surface plasmon resonance analysis showed had...
In 2016, direct-acting antiviral (DAA) treatment for hepatitis C (HCV) became available through Australia's universal health care system, with the aim of HCV elimination. We report real-world effectiveness DAA in Australia from a clinically well-informed cohort, enriched cirrhosis and prior treatment. 3413 patients were recruited 26 hospital liver clinics across February 2016 to June 2020. Clinical history sustained viral response (SVR) obtained medical records data linkage Australian...
First Nations Peoples of Australia are disproportionally affected by hepatitis C (HCV) infection. Through a prospective study we evaluated the outcome direct-acting antiviral (DAA) therapy among with HCV infection.Adults who initiated DAA at one 26 hospitals across Australia, 2016-2019 were included in study. Clinical data obtained from medical records and Pharmaceutical Medicare Benefits Schemes. Outcomes sustained virologic response (SVR) loss to follow-up (LTFU). A multivariable analysis...
Background Australia’s bowel cancer prevention guidelines, following a recent revision, are among the most complex in world. Detailed decision tables outline screening or surveillance recommendations for 230 case scenarios alongside cessation older patients. While these guidelines can help better allocate limited colonoscopy resources, their increasing complexity may limit adoption and potential benefits. Therefore, tools to support clinicians navigating could be essential national efforts....